Ernexa Therapeutics Inc. (ERNA) FCF Margin (2010 - 2024)
Ernexa Therapeutics' (ERNA) quarterly FCF Margin came in at 18652.63% in Q4 2024, down 1504243.0% YoY from N/an in Q1 2024, and down 1430.81% on a QoQ basis from 1218.48% in Q3 2024.
Ernexa Therapeutics Inc. (ERNA) FCF Margin (2010 - 2024) Analysis & Trends
Ernexa Therapeutics (ERNA) has 13 years of FCF Margin data on file, last reported at 18652.63% in Q4 2024.
- Quarterly FCF Margin fell 1504243.0% year-over-year to 18652.63% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 2639.0% (up 1778800.0% YoY) and the FY2024 annual result came in at 2639.0%, up 1778800.0% from the prior year.
- FCF Margin declined to 18652.63% in Q4 2024, from 1218.48% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 78.43% in Q1 2020 to a low of 18652.63% in Q4 2024.
- A 3-year average of 5952.39% and a median of 3610.2% in 2023 frame the typical range for FCF Margin.
- The widest YoY moves for FCF Margin: up 1496975 bps in 2024, down 1504243 bps in 2024.
- Tracing ERNA's FCF Margin over 3 years: stood at 137.15% in 2020, then tumbled by 2532 bps to 3610.2% in 2023, then plunged by 417 bps to 18652.63% in 2024.
- The last three FCF Margin figures came in at 18652.63% (Q4 2024), 1218.48% (Q3 2024), and 5336.17% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -18,652.63% |
| Sep 30, 2024 | -1,218.48% |
| Jun 30, 2024 | -5,336.17% |
| Mar 31, 2024 | -8,187.23% |
| Dec 31, 2023 | -3,610.20% |
| Sep 30, 2023 | -16,188.24% |
| Dec 31, 2020 | -137.15% |
| Sep 30, 2020 | -162.94% |
| Mar 31, 2020 | -78.43% |
| Dec 31, 2019 | 17.40% |
| Sep 30, 2019 | 3.91% |
| Jun 30, 2019 | -0.75% |
| Mar 31, 2019 | 15.29% |
| Dec 31, 2018 | 8.11% |
| Sep 30, 2018 | 7.03% |
| Jun 30, 2018 | 1.84% |
| Mar 31, 2018 | -5.02% |
| Dec 31, 2017 | -12.75% |
| Sep 30, 2017 | -37.40% |
| Jun 30, 2017 | 54.19% |